Molecular group:
Metabolic markers
Molecule/Cell:
Cysteamine (CysH)
Plasmodium strain:
Plasmodium chabaudi chabaudi AS
pRBC infection titer:
10^5
Mouse genetic background (Con):
A/J
Experimental treatment group (EG):
+ cysteamine hydrochloride (therapeutic treatment)
Lethal infection (Con):
♂ yes (100%); ♀ yes (35%)
Lethal infection (EG):
♂ yes (33-65%); ♀ yes (65-0%)
Pathology (Con):
N.I.
Pathology (EG):
N.I.
Parasitemia (EG vs Con):
Delayed onset and decreased
Additional phenotypes (EG vs Con):
The antimalarial effect and the effect on survival deminished when the onset of treatment was delayed; delayed ↑ of serum IFN-g and CCL2 (MCP-1) levels, ↓ serum CCL5 (RANTES) levels on d7 p.i., and similar serum levels of TNF, CCL4 (MIP-1b) and IL-10
Refs:
Min-Oo et al., 2010, Exp Parasitol
Hyperlink: